Adjudera

Supplier

Novartis Gene Therapies EU Ltd.

Dublin 9 · IRL

Awards

9

Total awarded

—

0 / 9 with a value

Buyers

1

Sectors

1

Reg. [Novartis Gene Therapies EU Ltd.]

Awards

AwardedBuyerWinnerContract valuePublished
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 60.5 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 55.0 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 52.3 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 38.5 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 35.8 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 33.0 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 30.3 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 27.5 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 22.0 mlPBMG eGNovartis Gene Therapies EU Ltd.—2 Mar 2026